Biodesix, Inc. · NASDAQ:BDSX
Biodesix — Investor Presentation (September 2021)
22 slides from Biodesix's investor presentation, Sep 9, 2021
Slide 1: Third Quarter 2021 Corporate Presentation
Third Quarter 2021 Corporate Presentation Exhibit 99.1
Slide 2: Disclaimer and forward-looking statements
This presentation and the accompanying oral presentation have been prepared by Biodesix, Inc. ("Biodesix", “we” or the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or represen
Slide 3: Introductions: presenting today
Robin Harper Cowie Chief Financial Officer Scott Hutton President & Chief Executive Officer Director of Payor & Government Relations Manager of Business Development Planning & Analysis SVP & General Manager of the Vascular Intervention division Former Laboratory Manager, Researcher Presenting today
Slide 4: Trusted partner for data-driven diagnostic solutions in lung disease
We strive to be a trusted partner that the world relies on for data-driven diagnostic solutions in lung disease by improving overall patient outcomes and lowering the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures.
Slide 5: We have tests for lung disease: Our Portfolio
We have 7 tests for lung disease Our Portfolio RESPIRATORY VIRUSES LUNG NODULES LUNG CANCER Tumor genetic profile – actionable tumor mutations Patients' immune response to cancer Identify likely benign nodules Identify likely malignant nodules Hospital Systems, Employers, Universities, State of Colo
Slide 6: Identifying clinical unmet needs in patient care
Identifying clinical unmet needs in patient care Lung Cancer Continuum of Care LUNG NODULE RISK ASSESSMENT pulmonologists CONFIRM DIAGNOSIS pulmonologists, thoracic surgeons TREATMENT DECISIONS medical oncologists, thoracic surgeons DIAGNOSIS TREATMENT DISEASE RECURRENCE & PROGRESSION medical oncolo
Slide 7: Understanding lung nodule management
Understanding lung nodule management CT Surveillance ? What Next? Diagnosis physician judgement risk calculators Very Low Risk (<5%) Low to Moderate Risk (5-65%) High Risk (>65%) 79.6% 9.5% 10.9% *USPSTF recently published a final recommendation statement to expand the eligible population for lung c
Slide 8: Blood-Based Nodule Risk Assessment
Full commercial launch March 2020 Full commercial launch October 2019 Medicare coverage with a unique CPT code & ADLT status ($3,520) Efforts ongoing with payers 4-day turnaround time Two studies ongoing (ALTITUDE & ORACLE) for combined lung nodule risk assessment and over 35 peer-reviewed publicati
Slide 9: Reclassifying risk to help reduce uncertainty in lung nodule management
Reclassifying risk to help reduce uncertainty in lung nodule management CT Surveillance Diagnosis solitary pulmonary nodule risk calculator (≤65% risk) Very Low Risk (<5%) Low to Moderate Risk (5-65%) High Risk (>65%) 79.6% 9.5% 10.9% Physician Judgement identifies likely malignant nodules with test
Slide 10: Treatment Guidance & Monitoring
Treatment Guidance & Monitoring Patients need to be given the right treatment as fast as possible tissue blood or Tumor Profile Immune Profile 4M+ molecular testing opportunities to guide NSCLC treatment decisions *In the NCCN Guidelines NSCLC v.1 2018, there were 34 treatment regimens (4 immunother
Slide 11: Blood-Based Tumor & Immune Profiling
VeriStrat Good (2x median survival) vs. VeriStrat Poor Mutations detected by ddPCR from blood DNA (SNV/Indels): BRAF | EGFR | KRAS RNA (Fusions): ALK | RET | ROS-1 Medicare and private payer coverage Not restricted by stage of NSCLC or multiple tests per patient per cancer Medicare and private payer
Slide 12: Where our peer-products fit along the patient treatment pathway
Where our peer-products fit along the patient treatment pathway Lung Cancer Continuum of Care LUNG NODULE RISK ASSESSMENT pulmonologists CONFIRM DIAGNOSIS pulmonologists, thoracic surgeons TREATMENT DECISIONS medical oncologists, thoracic surgeons DIAGNOSIS TREATMENT DISEASE RECURRENCE & PROGRESSION
Slide 13: Pipeline Products: Treatment Guidance & Monitoring
Next Generation Sequencing (NGS) 52-Gene Test Fastest test with 72-hour Turn-around time vs. 7-14 days, for guideline relevant mutations Synergies with existing GeneStrat ddPCR 6-gene test and VeriStrat tests Launch now expected first quarter of 2022 Risk of Recurrence Test (RoR) Host immune profili
Slide 14: Biopharma Services
Biopharma Services Driving near-term & long-term value creation and ongoing revenue 50+companies 150,000+ sample & data biobank Significant experience to date working with biopharma customers Select publicly-disclosed biopharma customers
Slide 15: Our suite of diagnostic testing solutions for biopharma customers
Our suite of diagnostic testing solutions for biopharma customers GeneStrat NGS (52 genes) Lung cfTNA Assay (12 genes) Lung cfDNA Assay (11 genes) Breast cfDNA Assay v2 (12 genes) Breast cfDNA Assay (10 genes) Colon cfDNA Assay (14 genes) Myeloid Assay (40 DNA genes + 29 fusions) Tumor Mutation Burd
Slide 16: Accomplishments and Updates
Accomplishments and Updates Continued expansion of sales force - doubling from 24 sales reps in 2020 to 48 in 2021 Launched cPass Neutralizing Antibody test for COVID-19 Announced launch of new 52-gene NGS test with unprecedented 72-hour turn around time Ordering Physicians, ordering Hospitals, and
Slide 17: Our Leadership Team
Extensive knowledge in diagnostics & reimbursement Our Leadership Team Scott Hutton CEO Robin Harper Cowie CFO Kieran O’Kane CCO Gary Pestano CDO (PhD) Robert Georgantas SVP Research (PhD) Paul Beresford CBO (PhD) Bobbi Coffin CGO James Jett CMO (MD) Steven Springmeyer CMO (MD) Linda Traylor VP CDMA
Slide 18: Company Summary
150K+ sample & data biobank We are a data-driven diagnostic solutions company Company Summary Experienced Leadership Team & Commercial Infrastructure Technology Agnostic Approach to Precision Medicine 7 lung focused diagnostic tests 450K+ tests performed 50+ biopharma customers $29B+ total US market
Slide 19: Appendix
W biodesix: Appendix
Slide 20: A Board of Directors with a vast amount of industry expertise
A Board of Directors with a vast amount of industry expertise Appendix Birchview Capital Crabtree Partners LLC
Slide 21: We have two certified, high-complexity laboratories
We have two certified, high-complexity laboratories Appendix CAP-accredited CLIA-certified NYS CLEP certified: Soluble Tumor Markers, Molecular & Cellular Tumor Markers and Virology ISO 13485-certified FDA Emergency Use Authorization CAP-accredited COLA-accredited NYS CLEP certified: Soluble Tumor M
Slide 22: Intellectual property portfolio
Intellectual property portfolio Appendix 87 issued patents 50 in the US and 37 foreign; 17 U.S. and 25 foreign applications still in various stages of prosecution 25 unique & active registered trademarks across 11 countries Patent Subject Matter: VeriStrat and Nodify tests and their uses in non-smal